Allergen Research Corporation Expands Management Wth New VP Functions

SAN MATEO, Calif.--(BUSINESS WIRE)--Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the appointments of Mary Rozenman, PhD, as Senior Vice President, Corporate and Commercial Development, and Mike Holfinger, PhD, as Vice President, Manufacturing.

Suggested Articles

CRISRP Therapeutics will likely be hit by the pandemic.

Pandion will test its lead program in patients with refractory ulcerative colitis and move a second program into phase 1.

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).